About Solid Biosciences
Solid Biosciences is a company based in Cambridge (United States) founded in 2014. Solid Biosciences has raised $92.5 million across 7 funding rounds from investors including Biogen, Janus Henderson Investors and RTW Investments. The company has 100 employees as of December 31, 2024. Solid Biosciences has completed 1 acquisition, including AAVANTIBio. Solid Biosciences offers products and services including Gene Therapy Candidates and Genetic Regulators Library. Solid Biosciences operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, Spark Therapeutics, MiRagen and Lundbeck, among others.
- Headquarter Cambridge, United States
- Employees 100 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Solid Biosciences Inc.
-
Annual Revenue
Not available
-
Net Profit
-$124.7 M (USD)-29.87as on Dec 31, 2024
-
EBITDA
-$127.27 M (USD)-25.1as on Dec 31, 2024
-
Total Equity Funding
$92.5 M (USD)
in 7 rounds
-
Latest Funding Round
$240 M (USD), Post-IPO
Mar 06, 2026
-
Investors
Biogen
& 17 more
-
Employee Count
100
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Solid Biosciences
Solid Biosciences is a publicly listed company on the NASDAQ with ticker symbol SLDB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Solid Biosciences
Solid Biosciences offers a comprehensive portfolio of products and services, including Gene Therapy Candidates and Genetic Regulators Library.
Treatments targeting rare neuromuscular diseases
Tools to enhance gene therapy delivery methods
People of Solid Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Solid Biosciences
Solid Biosciences has successfully raised a total of $92.5M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $240 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Solid Biosciences
Solid Biosciences has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Janus Henderson Investors and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked |
Investor details for Solid Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Solid Biosciences
Solid Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AAVANTIBio.
Investment portfolio details for Solid Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene transfer therapies for neuromuscular diseases are developed.
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for Solid Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Solid Biosciences
Detailed financials for Solid Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Solid Biosciences Comparisons
Peer comparison for Solid Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Solid Biosciences
Solid Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, Spark Therapeutics, MiRagen and Lundbeck, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
Detailed competitors of Solid Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solid Biosciences
Complete news archive for Solid Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Solid Biosciences
Solid Biosciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Solid Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Solid Biosciences is a funded company, having raised a total of $92.5M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Solid Biosciences is 100.
Solid Biosciences was founded in 2014 and is headquartered in Cambridge, United States. Focus is placed on biotechnology, specifically the development of gene therapy solutions for Duchenne muscular dystrophy. The primary candidate, SGT-001, features Microdystrophin, a synthetic dystrophin gene engineered to stabilize muscle membranes and the dystrophin-glycoprotein complex. A soft wearable device is also produced to support mobility and maintain muscle function for patients.
Solid Biosciences's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and Sana Biotechnology.
Solid Biosciences offers Gene Therapy Candidates and Genetic Regulators Library.
Yes, Solid Biosciences is publicly traded on NASDAQ under the ticker symbol SLDB.
Solid Biosciences has made 1 acquisition, including AAVANTIBio.
Solid Biosciences has 18 investors. Key investors include Biogen, Janus Henderson Investors, RTW Investments, RA Capital, and Perceptive Advisors.
The ticker symbol of Solid Biosciences is SLDB on NASDAQ.